ProCE Banner Activity

Contemporary Management of HIV: Integrating New Data From CROI 2020

Slideset Download
Download this expert-authored slideset to review the most clinically relevant new data presented at CROI 2020 covering a wide range of HIV management topics, including late-phase investigational ART strategies, weight gain and metabolic outcomes during ART, outcomes with ART during pregnancy, and rapid ART initiation.

Released: April 14, 2020

Expiration: April 13, 2021

No longer available for credit.

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Princy N. Kumar

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Program Director Disclosure

Program Director

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, and ViiV Healthcare.

Princy N. Kumar, MD

Professor of Medicine and Microbiology
Division of Infectious Diseases
Georgetown University Hospital
Division Chief
Division of Infectious Diseases and Travel Medicine
Department of Internal Medicine
Medstar Georgetown University Hospital
Washington, DC

Princy N. Kumar, MD, FIDSA, MACP, has disclosed that she has received consulting fees from Amgen, Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; has received funds for research support from Gilead Sciences, GlaxoSmithKline, Merck, and Theratechnologies; and has ownership interest in Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, and Pfizer.

Faculty Disclosure

Primary Author

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has disclosed that he has received consulting fees from Gilead Sciences, GlaxoSmithKline, Merck, and ViiV and funds for research support from Gilead Sciences, Merck, and ViiV.